Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.01 -1.6%	$3.20	$2.07 ▼ $4.20	$98.57M	0.43	108,018 shs	44,273 shs
CTNM Contineum Therapeutics	$5.96 +1.0%	$4.40	$3.35 ▼ $20.55	$152.64M	1.01	299,417 shs	262,492 shs
CTOR Citius Oncology	$2.06 -6.8%	$2.26	$0.55 ▼ $49.00	$173.20M	3.01	2.53 million shs	608,706 shs
ENLV Enlivex Therapeutics	$1.45 -2.7%	$1.13	$0.81 ▼ $1.76	$35.24M	0.8	231,549 shs	250,283 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-1.63%	-6.52%	-5.64%	+8.27%	-9.34%
CTNM Contineum Therapeutics	+1.02%	+3.29%	+49.00%	+45.37%	-70.29%
CTOR Citius Oncology	-6.79%	+4.57%	-60.54%	+122.70%	+205,999,900.00%
ENLV Enlivex Therapeutics	-2.68%	+29.23%	+28.32%	+39.42%	+8.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	3.3047 of 5 stars	3.6	5.0	2.1	3.3	0.0
CTNM Contineum Therapeutics	2.5052 of 5 stars	3.6	3.0	1.1	0.8	1.3
CTOR Citius Oncology	1.3467 of 5 stars	3.0	0.0	1.8	1.7	0.0
ENLV Enlivex Therapeutics	2.2211 of 5 stars	3.7	3.0	1.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.25	Buy	$9.00	199.00% Upside
CTNM Contineum Therapeutics	3.17	Buy	$22.50	277.52% Upside
CTOR Citius Oncology	2.00	Hold	$3.00	45.63% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	589.66% Upside

Current Analyst Ratings Breakdown

Latest ENLV, CTNM, ANIX, and CTOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	461.68	N/A	N/A	$0.59 per share	5.10
CTNM Contineum Therapeutics	$50M	3.08	N/A	N/A	$7.66 per share	0.78
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.64 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-53.88%	-18.86%	N/A
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)

Latest ENLV, CTNM, ANIX, and CTOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	N/A	N/A	N/A	$7.50 million	N/A
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/14/2025	Q2 2025	CTOR Citius Oncology	-$0.09	-$0.11	-$0.02	-$0.11	$5.74 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
CTNM Contineum Therapeutics	N/A	21.47	21.47
CTOR Citius Oncology	0.11	0.36	0.05
ENLV Enlivex Therapeutics	N/A	7.20	7.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
CTNM Contineum Therapeutics	N/A
CTOR Citius Oncology	70.52%
ENLV Enlivex Therapeutics	1.02%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
CTNM Contineum Therapeutics	11.30%
CTOR Citius Oncology	4.57%
ENLV Enlivex Therapeutics	12.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable

ENLV, CTNM, ANIX, and CTOR Headlines

Recent News About These Companies

D. Boral Capital Reiterates "Buy" Rating for Enlivex Therapeutics (NASDAQ:ENLV)

July 31 at 3:49 AM | americanbankingnews.com

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

July 28, 2025 | globenewswire.com

Enlivex Therapeutics' (ENLV) Buy Rating Reiterated at D. Boral Capital

July 24, 2025 | americanbankingnews.com

Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

June 13, 2025 | usatoday.com

Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona

June 11, 2025 | nasdaq.com

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

June 10, 2025 | globenewswire.com

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025 | globenewswire.com

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

April 23, 2025 | globenewswire.com

Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial

April 23, 2025 | msn.com

Enlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee Osteoarthritis

April 23, 2025 | nasdaq.com

Enlivex completed enrollment of patients in Phase II trial of Allocetra

April 22, 2025 | markets.businessinsider.com

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

April 21, 2025 | globenewswire.com

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth?

April 7, 2025 | finance.yahoo.com

Enlivex Therapeutics doses first patient in Phase I trial of Allocetra

April 4, 2025 | markets.businessinsider.com

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

April 3, 2025 | globenewswire.com

Enlivex Therapeutics Releases 2024 Financial Statements

March 31, 2025 | tipranks.com

Enlivex Therapeutics price target raised to $7 from $6 at H.C. Wainwright

March 24, 2025 | markets.businessinsider.com

Enlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for Osteoarthritis

March 19, 2025 | nasdaq.com

Enlivex to receive Chinese patent for use of Allocetra as a potential treatment in patients with osteoarthritis

March 19, 2025 | pharmabiz.comP

Enlivex Therapeutics receives notice of allowance for Chinese patent

March 17, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, CTNM, ANIX, and CTOR Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.01 -0.05 (-1.63%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.12 +0.11 (+3.65%)

As of 08/1/2025 07:12 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Contineum Therapeutics NASDAQ:CTNM

$5.96 +0.06 (+1.02%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.96 0.00 (0.00%)

As of 08/1/2025 06:33 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Citius Oncology NASDAQ:CTOR

$2.06 -0.15 (-6.79%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.18 +0.12 (+6.02%)

As of 08/1/2025 08:00 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Enlivex Therapeutics NASDAQ:ENLV

$1.45 -0.04 (-2.68%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.45 0.00 (0.00%)

As of 08/1/2025 07:53 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time